Andrew Poklepovic
Massey Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Andrew Poklepovic as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:04 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT04502602 · Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian CancerVirginia Commonwealth University · active not recruiting · Advanced Solid Tumor, Ovarian Cancer · principal investigator
- Ph1/Ph2NCT03919292 · Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated CaVirginia Commonwealth University · suspended · Solid Tumor, Adult · principal investigator
- Ph1NCT02349867 · Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic CancerVirginia Commonwealth University · completed · Pancreatic Adenocarcinoma, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer · principal investigator
- Ph2NCT01817751 · Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade GliomaVirginia Commonwealth University · completed · Glioblastoma, Recurrent Adult Brain Neoplasm, Malignant Glioma · principal investigator
- Ph1NCT01450384 · Pemetrexed Disodium and Sorafenib Tosylate in Treating Patients With Advanced Solid TumorsVirginia Commonwealth University · completed · Unspecified Adult Solid Tumor · principal investigator
- Ph1NCT00580320 · Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue SarcomaVirginia Commonwealth University · completed · Melanoma, Soft Tissue Sarcoma, Parathyroid Carcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:04 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Clinical Protocol and Data Management (CPDM)P30CA016059 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · fiscal years 2021 to 2025 · $243,481 awarded in 2025Grant number is on one of their registry trials
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:04 UTC. The ranking covers the 200 most relevant of 19 PubMed records, and a shared surname and initials can bring in a namesake. All 19 on PubMed
- Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.N Engl J Med · 2023784 citationsRCR 65.0
- 456 citationsRCR 30.1
- Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma.J Clin Oncol · 2021184 citationsRCR 8.3
- Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers.J Clin Invest · 2021108 citationsRCR 5.3
- Effect of Taxane Chemotherapy With or Without Indoximod in Metastatic Breast Cancer: A Randomized Clinical Trial.JAMA Oncol · 202151 citationsRCR 2.3
- A multi-institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer.Cancer · 202038 citationsRCR 1.5
- Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma.Am J Clin Oncol · 201932 citationsRCR 1.1
- T-cell immune checkpoint inhibition plus hypomethylation for locally advanced HER2-negative breast cancer: a phase 2 neoadjuvant window trial of decitabine and pembrolizumab followed by standard neoadjuvant chemotherapy.J Immunother Cancer · 202521 citationsRCR 4.3
- Neratinib decreases pro-survival responses of [sorafenib + vorinostat] in pancreatic cancer.Biochem Pharmacol · 202017 citationsRCR 0.6
- SWOG/NCI Phase II Dual Anti-CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian Cancer.Clin Cancer Res · 202414 citationsRCR 1.5